Retatrutide hits 20% weight loss at 80 weeks in TRIUMPH-1 phase 3
An ADA 2026 interview recaps late-stage data on retatrutide, survodutide, oral GLP-1s and amylin agents presented in New Orleans.
PR
By Priya Raman · Science Reporter
Jul 6 03:00 ETSource: DocWireNews
The wire
- 01In TRIUMPH-1, the triple GLP-1/GIP/glucagon agonist retatrutide produced about 20% weight change at 80 weeks in adults with obesity, with the top dose exceeding 30% in an extension to 104 weeks.
- 02Obesity specialist Michael Weintraub says glucagon agonism, oral GLP-1s and amylin backbones are broadening options beyond single-mechanism injectables.
- 03The account is a conference interview, not a full publication; efficacy-estimand figures reflect patients remaining on drug, and TRANSCEND-T2D-1 details were not given.
From the source
Read at docwirenews.comADA 2026 Obesity Drug Updates: Retatrutide, CagriSema, and Oral GLP-1s
At the 2026 American Diabetes Association Scientific Sessions, investigators unveiled a wave of late-stage obesity trial results that could reshape clinical practice. In this interview, Michael Weintraub, MD, discusses key findings from studies of retatrutide, survodutide, oral GLP-1 receptor agonists, and amylin-based therapies. He explores how glucagon agonism is driving weight loss toward the b